Cadrenal Therapeutics Inc. will attend the BIO International Convention 2025, which takes place from June 16-19 in Boston. The company's executive leadership team will engage in one-on-one meetings with investors and potential partners to discuss the strategic direction and clinical development of its lead asset, tecarfarin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.